RxDoctor Payments Data

Maria Servioli Verde, MD

Neurology · Redding, CANPI 1205169109

Payments from drug & device makers

$8,515in general payments, 2019–2025

Across 188 payments — averaging $45.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • AbbVie$1K
  • Medtronic$807
  • Acadia Pharmaceuticals Inc$299
  • MDD US Operations, LLC$260
  • Neurocrine Biosciences, Inc.$165
  • plus $2K from 34 others

What the payments were for

  • Travel & lodging$3,58142%
  • Food & beverage$4,92158%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,515 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$317,558
Medicare patients
722
Services billed
10,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate44$382,475
RytaryCarbidopa/Levodopa212$281,149
AustedoDeutetrabenazine62$268,558
Droxidopa41$109,579
NuplazidPimavanserin Tartrate19$91,354
Austedo XrDeutetrabenazine12$85,939
InbrijaLevodopa60$66,686
GocovriAmantadine Hcl18$59,134
Carbidopa-LevodopaCarbidopa/Levodopa792$28,843
SinemetCarbidopa/Levodopa61$20,281
NeuproRotigotine14$11,530
Carbidopa-Levodopa ErCarbidopa/Levodopa252$10,691
Aimovig AutoinjectorErenumab-Aooe11$8,072
AmantadineAmantadine Hcl141$5,941
MyrbetriqMirabegron11$5,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$165$382,47544 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$20$354,49674 claims
Amneal Pharmaceuticals LLCRytary$80$281,149212 claims
Acadia Pharmaceuticals IncNuplazid$299$91,35419 claims
Acorda Therapeutics, IncInbrija$21$66,68660 claims
MDD US Operations, LLCGocovri$260$59,13418 claims
UCB, Inc.Neupro$111$11,53014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →